gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone meta..
breast-tissue sampling for risk assessment and prevention
tissue inhibitor of metalloproteinases-1 in breast cancer
low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma
life expectancy in differentiated thyroid cancer: a novel approach to survival analysis
medullary and papillary carcinoma of the thyroid gland occurring as a collision tumour: report of three cases with molecular analysis and review of the literature
action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture
characterization of thyroid ‘follicular neoplasms’ in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for cl..
mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours
braf mutation in thyroid cancer
identification of growth factor independent-1 (gfi1) as a repressor of 25-hydroxyvitamin d 1-alpha hydroxylase (cyp27b1) gene expression in human prostate cancer ce..
alterations in the regulatory volume decrease (rvd) and swelling-activated cl
evidence for specific trpm8 expression in human prostate secretory epithelial cells: functional androgen receptor requirement
cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-in..
the 67 kda laminin receptor increases tumor aggressiveness by remodeling laminin-1
gonadotropins upregulate the epidermal growth factor receptor through activation of mitogen-activated protein kinases and phosphatidyl-inositol-3-kinase in human ov..
enhanced protein kinase b/akt signalling in pituitary tumours
chromosomal instability predicts metastatic disease in patients with insulinomas
malign cystic glucagonoma presented with diabetic ketoacidosis: case report with an update
er is a potent inhibitor of cell proliferation in the hct8 human colon cancer cell line through regulation of cell cycle components
overview of the impact of conventional systemic therapies on breast cancer
the epidermal growth factor receptor family
growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or del..
the nfb pathway and endocrine-resistant breast cancer
long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity
elevated erk1/erk2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation
downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-myc, cyclin d1 and cyclin e
acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new mcf-7x model
epidermal growth factor receptor/her2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer
growth factor signalling and response to endocrine therapy: the royal marsden experience
growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: the edinburgh experience
growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy
overview of tyrosine kinase inhibitors in clinical breast cancer
clinical trials of intracellular signal transductions inhibitors for breast cancer ― a strategy to overcome endocrine resistance
intrinsic and acquired resistance to egfr inhibitors in human cancer therapy
inhibitors of growth factor signalling
development of strategies for the use of anti-growth factor treatments